Searched for
US PHARMACEUTICAL TARIFFS
These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsAfter four days of relative outperformance, the Indian market is seemingly in trouble: Both the indices (the Nifty and Sensex) and market b...- Trump's 200% generic drug tariff threat puts $9.7 billion Indian pharma exports at risk; industry says reshoring not practicalUS President Trump's proposed tariffs on imported generic drugs will not immediately affect Indian drugmakers. Indian companies export sign...
- 'I expect India to be concerned about US pharma tariffs': Rubio on Trump's 200% stormUS Secretary of State Marco Rubio anticipates Indian concern over new generic drug import tariffs. These tariffs will rise significantly af...
- Pharma stocks slide as Trump's 100% generic drug tariff plan spooks investorsIndian drug shares declined Wednesday following US President Trump's tariff announcement. These proposed tariffs will significantly impact ...
- Tariff hike by US will only increase drug prices: Dr Reddy's CEOUS tariff increases on generic medicines will lead to higher drug prices in India. Dr Reddy's Laboratories CEO Erez Israeli stated relocati...
- Ahead of Market: 10 things that will decide stock market action on ThursdayIndian stock markets experienced significant declines on Wednesday. Escalating global tensions and inflation concerns spooked investors, le...
- Tariffs alone will not produce sustainable generic medicine in US: IPAThe Indian Pharmaceutical Alliance believes tariffs alone will not build US generic drug manufacturing. Broader reforms are needed for fair...
- US-India trade deal could be signed in 3-4 months, US official saysA U.S.-India trade agreement is nearing completion and could be signed soon. Negotiations are virtually finished, with only U.S. trade inve...
- Explained: What Donald Trump's up to 200% pharma tariffs mean for Indian investorsDonald Trump's announcement of tariffs of up to 200% on pharmaceutical imports triggered a selloff in Indian pharma stocks. However, analys...
- Indian pharma firms may yet survive Trump's 200% tariff bombshellDonald Trump's proposed up to 200% tariff on generic drug imports has raised concerns for Indian pharma companies, but industry experts say...
- 200% Trump tariff shock? India’s cheap pills may still beat US rivalsUS President Donald Trump's proposed tariffs of up to 200% on imported generic medicines could put pressure on India's pharmaceutical expor...
- Trump’s 100% generic drug duty threatens US low-cost supplyPresident Donald Trump has given generic drugmakers two years to shift manufacturing to the US or face 100% import tariffs from August 2028...
- Trump's Generic Drug Tariffs Explained: What it means for Indian pharma before the 200% stormTrump's generic drug tariffs plan provides Indian drugmakers a two-year duty-free window. This allows companies time to reassess manufactur...
- Trump's 200% drug tariff plan: Is India's pharma industry about to face an economic storm?The United States is set to implement a phased approach to tariffs on generic drug imports, beginning at zero percent and escalating to one...
- Trump announces new generic drugs tariff plan: No tariffs for 2 years, then 100%, and then 200%For Indian exporters, the two-year tariff-free period offers additional time to reassess supply chains and investment plans. While the imme...
- Sun Pharma, Cipla & other pharma stocks shed over 2% as Trump announces up to 200% tariffs on generic drugs from 2028Pharma stocks, including Sun Pharma, Cipla, Lupin and Dr Reddy's, fell up to 2.5% after US President Donald Trump announced a phased tariff...
- AI bigger risk to IT workers than companies, says Marcellus’ Pramod GubbiArtificial intelligence may reduce Indian IT sector employment before impacting companies. Valuations are less compelling now after recent ...
- India-UK FTA comes into force: Industry hails ‘landmark moment’ for bilateral tradeThe Comprehensive Economic and Trade Agreement between India and the UK is now active. This pact aims to significantly boost bilateral trad...
- Stocks, gold and debt: Why ICICI Pru’s Dharmesh Kakkad favours a multi-asset strategy nowICICI Prudential's Dharmesh Kakkad advises investors against chasing the best-performing asset classes, arguing that a dynamic multi-asset ...
- India should resist early concessions in US trade talks: SBI reportIndia should remain patient and avoid making early concessions in its ongoing trade negotiations with the United States, as Washington's cu...
Load More
